2-(2-溴乙氧基)乙醇 | 57641-66-4

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪醇
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(2-溴乙氧基)乙醇
• 英文名称: 2-(2-bromoethoxy)ethanol
• 英文别名: 2-(2-bromoethoxy)ethan-1-ol；2-bromoethoxyethanol
• CAS: 57641-66-4
• 化学式: C₄H₉BrO₂
• mdl: MFCD20621572
• 分子量: 169.018
• InChiKey: JTOJLOUPDKBCCH-UHFFFAOYSA-N

物化性质

• 沸点：
  228.9±15.0 °C(Predicted)
• 密度：
  1.514±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  7
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  -20°C，干燥

制备方法与用途

Bromo-PEG2-alcohol是一种PROTAC连接子，属于PEG类化合物，可用于合成PROTAC分子。

反应信息

• 作为反应物：
  描述：

  2-(2-溴乙氧基)乙醇 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 2-(2-bromoethoxy)ethanaldehyde
  参考文献：
  名称：

  乙缩醛与内酰胺的有机催化不对称曼尼希环化反应：（-）-埃皮帕宁，（-）-Tashiromine和（-）-Trachelanthamidine的总合成

  摘要：

  羟基内酰胺和乙缩醛之间的不对称有机催化单锅曼尼希环化反应可提供带有桥头N原子的稠合双环生物碱。脂肪族和芳香族底物均用于该转化中，以高达89％的收率和97％的ee值提供手性吡咯烷酮，吲哚啶酮和喹喔啉酮衍生物。（-）-癫痫素，（-）-tashiromine和（-）-trachelanthamidine的总合成也证明了该方法的普遍性。

  DOI：

  10.1002/anie.201407185
• 作为产物：
  描述：

  二乙二醇 在 氢溴酸 作用下， 以 水 、 甲苯 为溶剂， 反应 4.0h， 以87%的产率得到2-(2-溴乙氧基)乙醇
  参考文献：
  名称：

  乙缩醛与内酰胺的有机催化不对称曼尼希环化反应：（-）-埃皮帕宁，（-）-Tashiromine和（-）-Trachelanthamidine的总合成

  摘要：

  羟基内酰胺和乙缩醛之间的不对称有机催化单锅曼尼希环化反应可提供带有桥头N原子的稠合双环生物碱。脂肪族和芳香族底物均用于该转化中，以高达89％的收率和97％的ee值提供手性吡咯烷酮，吲哚啶酮和喹喔啉酮衍生物。（-）-癫痫素，（-）-tashiromine和（-）-trachelanthamidine的总合成也证明了该方法的普遍性。

  DOI：

  10.1002/anie.201407185

文献信息

• Mono- and dicationic short PEG and methylene dioxyalkylglycerols for use in synthetic gene delivery systems
  作者：Christopher A. Hurley、John B. Wong、Jimmy Ho、Michele Writer、Scott A. Irvine、M. Jayne Lawrence、Stephen L. Hart、Alethea B. Tabor、Helen C. Hailes

  DOI：10.1039/b719702k

  日期：——

  A range of monocationic and dicationic dioxyalkylglycerol cytofectins have been synthesised possessing methylene and short n-ethylene glycol spacers. The monocationic compounds were found to be effective in transfections when formulated as lipopolyplexes with peptide and DNA components, in particular with shorter PEG head groups which may have less effect on peptide targeting in the ternary complex.

  一系列单阳离子和双阳离子二氧烷基甘油细胞转染剂已被合成出来，它们具有亚甲基和短的正乙烯二醇间隔基。单阳离子化合物在与多肽和DNA成分组成的脂质复合物配方中被发现具有有效的转染效果，尤其是带有较短PEG头部基团的化合物，这些头部基团可能在三元复合物中对多肽的靶向性影响较小。
• [EN] PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉ CHIMÈRE CIBLANT LA PROTÉOLYSE (PROTAC) AYANT UNE ACTIVITÉ DE LIAISON À L'UBIQUITINE LIGASE E3 ET CIBLANT UNE PROTÉINE ALPHA-SYNUCLÉINE POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2020041331A1

  公开（公告）日：2020-02-27

  The present disclosure relates to bifunctional compounds, which find utility as modulators of alpha-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/ inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure. Such diseases or disorders are alpha-synucleinopathies or neurodegenerative diseases associated with alpha-synuclein accumulation and aggregation, such as e.g. Parkinson Disease, Alzheimer's Disease, dementia, dementia with Lewy bodies or multiple system atrophy, in particular Parkinson's Disease.

  本公开涉及双功能化合物，其作为α-突触核蛋白（目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，另一端为与目标蛋白结合的基团，使得目标蛋白靠近泛素连接酶以促使目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。这些疾病或紊乱是与α-突触核蛋白积累和聚集相关的α-突触核蛋白病或神经退行性疾病，例如帕金森病、阿尔茨海默病、痴呆症、带有Lewy小体的痴呆症或多系统萎缩，特别是帕金森病。
• Design and Synthesis of Novel Anti-Proliferative Emodin Derivatives and Studies on their Cell Cycle Arrest, Apoptosis Pathway and Migration
  作者：Kun Yang、Ming-Ji Jin、Zhe-Shan Quan、Hu-Ri Piao

  DOI：10.3390/molecules24050884

  日期：——

  Emodin is a cell arrest and apoptosis-inducing compound that is widely distributed in different plants (rhubarb, aloe), lichens and terrestrial fungi, and also isolated from marine-derived fungi and marine sponge-associated fungi. In this study, we designed and synthesized a novel series of emodin derivatives by binding emodin to an amino acid using linkers of varying lengths and composition, and evaluated their anti-proliferative activities using HepG2 cells (human hepatic carcinoma), MCF-7 cells (human breast cancer) and human normal liver L02 cells. Most of these derivatives showed moderate to potent anti-proliferative activities. Notably, compound 7a exhibited potent anti-proliferative activity against HepG2 cells with the half maximal inhibitory concentration (IC50) value of 4.95 µM, which was enhanced 8.8-fold compared to the parent compound emodin (IC50 = 43.87 µM), and it also exhibited better selective anti-proliferative activity and specificity than emodin. Moreover, further experiments demonstrated that compound 7a displayed a significant efficacy of inducing apoptosis through mitochondrial pathway via release of cytochrome c from mitochondria and subsequent activation of caspase-9 and caspase-3, inducing cell arrest at G0/G1 phase, as well as suppression of cell migration of tumor cells. The preliminary results suggested that compound 7a could be a promising lead compound for the discovery of novel anti-tumor drugs and has the potential for further investigations as an anti-cancer drug.

  大黄素是一种引起细胞停滞和凋亡的化合物，广泛分布于不同植物（大黄、芦荟）、地衣和陆生真菌，同时也从海洋真菌和海绵相关真菌中分离出来。在这项研究中，我们设计并合成了一系列新型的大黄素衍生物，通过使用长度和组成不同的连接剂将大黄素与氨基酸结合，评估它们在HepG2细胞（人肝癌）、MCF-7细胞（人乳腺癌）和人正常肝细胞L02中的抗增殖活性。这些衍生物中大多数显示出中等到强效的抗增殖活性。值得注意的是，化合物7a对HepG2细胞表现出强效的抗增殖活性，半数抑制浓度（IC50）值为4.95 µM，比母体化合物大黄素（IC50 = 43.87 µM）提高了8.8倍，而且它还表现出比大黄素更好的选择性抗增殖活性和特异性。此外，进一步的实验表明，化合物7a通过线粒体途径释放细胞色素c并随后激活caspase-9和caspase-3诱导凋亡，使细胞在G0/G1期停滞，同时抑制肿瘤细胞的迁移。初步结果表明，化合物7a可能是发现新型抗肿瘤药物的有希望的先导化合物，并具有进一步作为抗癌药物进行研究的潜力。
• [EN] MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE MCL-1 MACROCYCLIQUE ET PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2019035927A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y的化合物，这些化合物的任何值均在规范中定义，并且其药学上可接受的盐，可用作治疗疾病和病况，包括癌症的药物。还提供了包含Formula (I)中化合物的药物组合物。
• Sequence-Selective Synthesis of Rotacatenane Isomers
  作者：Ryuto Hayashi、Petr Slavík、Yuichiro Mutoh、Takeshi Kasama、Shinichi Saito

  DOI：10.1021/acs.joc.5b02697

  日期：2016.2.5

  interlocked compound composed of two mechanically interlocked macrocyclic components, i.e., a [2]catenane, and one axle component. In this paper we describe the selective synthesis of isomeric rotacatenanes. Two [2]rotaxanes with different phenanthroline moieties were synthesized by the oxidative coupling of an alkyne with a bulky blocking group, which proceeded in the cavity of the macrocyclic phenanthroline–Cu

  Rotacatenane是一种互锁的化合物，它由两个机械互锁的大环组分（即[2] catenane）和一个车轴组分组成。在本文中，我们描述了旋转异构体异构体的选择性合成。通过炔基与大嵌段基团的氧化偶联，合成了具有不同菲咯啉部分的两种[2]轮烷，该偶联反应在大环菲咯啉-Cu络合物的空腔中进行。金属模板法用于安装另一种环状组分：合成了由[2]轮烷和无环菲咯啉衍生物组成的四面体Cu（I）配合物，并且菲咯啉衍生物的环化反应得到了rotacatenane。旋转儿茶酚的顺序异构体的区别在于1 H和1313 C NMR光谱。